Scotiabank

Scotiabank, founded in 1832 and headquartered in Toronto, Canada, is a leading financial institution that serves approximately 21 million customers in over 55 countries. The bank offers a comprehensive range of banking products and services, including personal and commercial banking, investment banking, wealth management, and insurance. Its private equity arm focuses on middle-market investments, specializing in sectors such as healthcare, technology, and consumer products. Scotiabank typically invests between $5 million and $25 million in companies, seeking both minority and majority ownership stakes. With a commitment to managing risk and capital effectively, Scotiabank aims to support individuals, businesses, and communities in achieving financial success. The organization employs over 86,000 people dedicated to understanding customer needs and delivering tailored financial solutions.

Phil Armstrong

Senior Vice President, Specialized Financial Services

Paul Baroni

CFO, Finance and Executive Vice President

Charles Comiskey

Managing Director

Angela Van Damme

Vice President

Daniel Kennedy

Vice President, Chile

Martine Lamoureux

Senior Vice President, Global Enterprise Technology

Jake Lawrence

CEO and Group Head

James Neate

Executive and President

Adrian Rosiles

Executive Vice President and Executive

Jabar Singh

Senior Vice President and Head, Wholesale Banking (Chile)

Albert wahbe

Chairman and CEO of e-Scotia

Dan Waldner

Director of Customer Data

Past deals in Diversified

Artis REIT

Post in 2022
Artis is a diversified Canadian real estate investment trust investing in industrial and office properties in Canada and the United States. Since 2004, Artis has executed an aggressive but disciplined growth strategy, building a portfolio of commercial properties in select markets in Canada and the United States. As of September 30, 2020, Artis' commercial property comprises approximately 23.8 million square feet of leasable area.

DRI Healthcare Trust

Post in 2021
DRI Healthcare Trust provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Our business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties with the aim to deliver attractive growth in cash royalty receipts over the long term.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.